IQVIA Holdings Inc. reported second-quarter 2026 financial results, announcing revenue of $4,368 million, an 8.7% year-over-year increase. GAAP diluted earnings per share were $1.53, while adjusted diluted EPS rose 12.1% to $3.15. The company generated $994 million in adjusted EBITDA and $558 million in operating cash flow. R&D Solutions net new bookings reached a record $3.15 billion, up 19% year-over-year. IQVIA raised its full-year 2026 guidance, projecting revenue between $17.275 billion and $17.475 billion, adjusted EBITDA between $4.0 billion and $4.05 billion, and adjusted diluted EPS between $12.80 and $13.00. The company operates in the clinical research services, commercial insights, and healthcare intelligence industry.

IQVIA Inc. completed the issuance and sale of €950,000,000 in gross proceeds of 4.625% senior notes due 2033. The net proceeds will be used to refinance existing indebtedness and cover offering-related fees and expenses. IQVIA Holdings Inc. is a provider of advanced analytics and clinical research services for the healthcare industry.

IQVIA Holdings Inc. has authorized an additional $2,000 million for the repurchase of its common stock under its existing equity repurchase program. This increase brings the total remaining authorization for the program to $3,217 million.

IQVIA Holdings Inc. issued a press release on May 5, 2026, announcing its financial results for the first quarter ended March 31, 2026. The filing serves to disclose the company's quarterly results of operations and financial condition via an attached press release.